Latham & Watkins Advises IDEAYA Biosciences on US$300 Million Offering of Common Stock and Pre‑Funded Warrants

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) has announced the pricing of an underwritten public offering of common stock and pre‑funded warrants. IDEAYA is selling 5,555,556 shares of common stock and pre‑funded warrants to purchase 5,555,576 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of US$27 per share, before underwriting discounts and commissions, and the pre‑funded warrants are being sold at a public offering price of US$26.9999 per pre‑funded warrant. The exercise price of the pre‑funded warrants is US$0.0001 per share. In addition, IDEAYA has granted the underwriters a 30‑day option to purchase up to an additional 1,666,669 shares of its common stock at the public offering price per share, before underwriting discounts and commissions. The aggregate gross proceeds to IDEAYA from this offering are expected to be approximately US$300 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre‑funded warrants. The offering is expected to close on or about June 10, 2026, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents IDEAYA Biosciences in the offering with a corporate team led by Bay Area partners Mark Roeder and John Williams, with associates Caitlin Nguyen, Sheen Moaleman,* and Isaac Gonzalez. Advice was also provided on intellectual property and technology transactions matters by San Diego counsel Robert Yeh, with associate Kristina Funahashi; on tax matters by Bay Area partner Grace M. Lee, with associates Derek Gumm and Tessa Young; on FDA regulatory matters by Washington, D.C. partner John Manthei and Bay Area partner Betty Pang, and San Diego counsel Amy Speros; and on executive compensation and benefits matters by Bay Area partner James Metz.

*Admitted to practice in New York only.